September 16, 2014 14:00 ET

DIAGNOS Announces Contract with Dr. Kovil's Diabetes Care Centre in Mumbai

BROSSARD, QUEBEC--(Marketwired - Sept. 16, 2014) - Diagnos Healthcare India Pvt. Ltd. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with Dr. Kovil's Diabetes Care Centre in Mumbai for one retinopathy screening unit.

The Diabetes Care Centre is a combination of a preventive diabetes center and a diabetic foot clinic in terms of both equipment and expertise. The diabetic care centre is run as per Mayo Diabetes Center and American Diabetes Association guidelines, while the Foot Clinic is run as per the guidelines provided by the American Ankle & Foot Society. "The general attitude of diabetic patients is a direct jump from ailment to cure; very few understand the significance of preventive measures. The cost of medical expenses is also escalating, so it is high time that diabetic patients understand that prevention is cheaper than cure" states Dr. Kovil.

"After establishing a local presence in India less than a year ago, DIAGNOS has been working hard at establishing itself as the go-to provider for diabetic retinopathy screening services via excellent customer service and flexible turn-key screening options. We also run a mobile screening van within the country, allowing us to interact with many potential clients. As a result of our efforts, more and more physicians are expressing interest in our services," said André Larente, Diagnos' President.


Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

About DIAGNOS Healthcare India Pvt. Ltd.

DIAGNOS Healthcare India Pvt. Ltd. is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Indian Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in India.

Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness around the world. It is a treatable disease that, as with most diseases, has a higher treatment success rate in its earlier stages. However, there are generally no symptoms until the disease has progressed to more severe stages, making early detection critical to helping prevent vision loss. India has a population of 1.24 billion people and, according to the International Diabetes Federation, has a diabetic population of 65 million.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com

Contact Information

  • Andre Larente, President
    DIAGNOS Inc.
    Tel. : (450) 678-8882 ext 224